What's Happening?
Pleno Inc., a biotechnology company based in San Diego, has entered into a commercial agreement with Slopes Bio, Inc., a high-complexity accredited laboratory. This partnership marks the official commercial launch of Pleno's RAPTOR instrument platform, which is designed for biological target detection and personalized health applications. Slopes Bio will utilize Pleno's RAPTOR instruments and consumables to process over 100,000 samples annually. The collaboration includes the development of a polygenic risk score panel, with clinical data showing improved accuracy and cost efficiency using Pleno's Hypercoding technology. The agreement involves the purchase of up to five RAPTOR instruments, with the first two set to be deployed in Slopes' Utah-based lab later this month.
AD
Why It's Important?
The partnership between Pleno Inc. and Slopes Bio, Inc. is significant for the biotechnology and healthcare industries as it introduces a scalable solution for high-throughput biological analysis. The RAPTOR platform's ability to process large volumes of samples efficiently could transform personalized medicine, offering more accurate and cost-effective solutions for health and wellness testing. This collaboration positions both companies to meet the growing demand for advanced biological analysis, potentially benefiting patients through improved diagnostic capabilities and personalized treatment options.
What's Next?
Pleno and Slopes Bio plan to expand their collaboration beyond the initial deployment of RAPTOR instruments. They aim to develop multiple high-sample-volume applications to address increasing market demand for efficient and scalable solutions in personalized health testing. The companies are expected to publish a white paper detailing the benefits of Hypercoding technology, which could further validate the platform's effectiveness and encourage wider adoption in the industry.
